Adjuvant nab-paclitaxel plus S-1 versus oxaliplatin plus capecitabine after curative D2 gastrectomy in patients with stage III gastric adenocarcinoma: a phase 3 open-label, randomized controlled trialYu Pengfei, Xiangdong Cheng, Yunhai Wei et al.|Journal of Clinical Oncology|2023Cited by 1
A randomized, controlled, multi-center, open-label study of adjuvant nab-paclitaxel plus S-1 (AS) versus capecitabine plus oxaliplatin (CapeOX) for stage III gastric cancer after D2 resection.Yu Pengfei, Xiangdong Cheng, Yian Du et al.|Journal of Clinical Oncology|2022Cited by 0
Adjuvant nab-paclitaxel plus S-1 versus capecitabine plus oxaliplatin for patients with stage III gastric adenocarcinoma after D2 dissection: A multicenter, open-label, randomized phase 3 study.Yu Pengfei, Xiangdong Cheng, Yian Du et al.|Journal of Clinical Oncology|2023Cited by 0